Last reviewed · How we verify
Experimental: YZJ-4729
Experimental: YZJ-4729 is a Small molecule drug developed by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. It is currently in Phase 3 development.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Experimental: YZJ-4729 |
|---|---|
| Sponsor | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery (PHASE2)
- A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery (PHASE3)
- A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental: YZJ-4729 CI brief — competitive landscape report
- Experimental: YZJ-4729 updates RSS · CI watch RSS
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd. portfolio CI
Frequently asked questions about Experimental: YZJ-4729
What is Experimental: YZJ-4729?
Who makes Experimental: YZJ-4729?
What development phase is Experimental: YZJ-4729 in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing